Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Compare

1,087 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RARE Analyst Ratings

Strong Buy

13 Buy

1 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Ultragenyx

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RARE Stock 12 Month Forecast

Average Price Target

$76.31

▲(129.77% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $76.31 with a high forecast of $120.00 and a low forecast of $35.00. The average price target represents a 129.77% change from the last price of $33.21.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"$27","74":"$74","121":"$121","50.5":"$50.5","97.5":"$97.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76.3076923076923,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$76.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,50.5,74,97.5,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.37,40.03384615384615,46.69769230769231,53.36153846153846,60.02538461538461,66.68923076923076,73.35307692307691,80.01692307692306,86.68076923076922,93.34461538461537,100.00846153846152,106.67230769230767,113.33615384615385,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.37,36.672899408284025,39.975798816568044,43.27869822485207,46.58159763313609,49.88449704142012,53.18739644970414,56.490295857988166,59.79319526627219,63.09609467455621,66.39899408284023,69.70189349112425,73.00479289940829,{"y":76.3076923076923,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.37,33.495384615384616,33.62076923076923,33.746153846153845,33.87153846153846,33.996923076923075,34.12230769230769,34.247692307692304,34.37307692307692,34.49846153846154,34.62384615384615,34.74923076923077,34.87461538461538,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":47.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.97,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$76.31

Lowest Price Target$35.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gavin Clark-Gartner

Evercore ISI

$70

Buy

110.78%

Upside

Reiterated

12/17/25

Evercore ISI Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Benjamin Burnett

Wells Fargo

$65

Buy

95.72%

Upside

Reiterated

12/17/25

Wells Fargo Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Yigal Nochomovitz

Citi

$103

Buy

210.15%

Upside

Reiterated

12/02/25

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Citi

Gena Wang

Barclays

$81→$50

Buy

50.56%

Upside

Reiterated

11/24/25

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Barclays

Kristen Kluska

Cantor Fitzgerald

$105

Buy

216.17%

Upside

Reiterated

11/20/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Anupam Rama

J.P. Morgan

$125→$120

Buy

261.34%

Upside

Reiterated

11/18/25

J.P. Morgan Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Joon Lee

Truist Financial

$90

Buy

171.00%

Upside

Reiterated

11/05/25

Ultragenyx Pharmaceutical (RARE) Gets a Buy from Truist Financial

Yaron Werber

TD Cowen

$86→$75

Buy

125.84%

Upside

Reiterated

11/05/25

TD Cowen Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Laura Chico

Wedbush

$35

Hold

5.39%

Upside

Reiterated

11/05/25

Maxwell Skor

Morgan Stanley

$55

Buy

65.61%

Upside

Reiterated

11/05/25

Ultragenyx Pharmaceutical Positioned for Success with Strategic Financing and Promising Setrusumab Trials

Sami Corwin

William Blair

Buy

―

Reiterated

11/05/25

Positive Outlook for Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Financial Strength and Product Growth

Tazeen Ahmad

Bank of America Securities

$74→$72

Buy

116.80%

Upside

Reiterated

11/05/25

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Bank of America Securities

Luca Issi

RBC Capital

$77→$72

Buy

116.80%

Upside

Reiterated

11/05/25

RBC Capital Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Ram Selvaraju

H.C. Wainwright

$80

Buy

140.89%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Exelixis (NASDAQ: EXEL)

Joseph Schwartz

Leerink Partners

Buy

―

Reiterated

09/08/25

Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gavin Clark-Gartner

Evercore ISI

$70

Buy

110.78%

Upside

Reiterated

12/17/25

Evercore ISI Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Benjamin Burnett

Wells Fargo

$65

Buy

95.72%

Upside

Reiterated

12/17/25

Wells Fargo Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Yigal Nochomovitz

Citi

$103

Buy

210.15%

Upside

Reiterated

12/02/25

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Citi

Gena Wang

Barclays

$81→$50

Buy

50.56%

Upside

Reiterated

11/24/25

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Barclays

Kristen Kluska

Cantor Fitzgerald

$105

Buy

216.17%

Upside

Reiterated

11/20/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Anupam Rama

J.P. Morgan

$125→$120

Buy

261.34%

Upside

Reiterated

11/18/25

J.P. Morgan Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Joon Lee

Truist Financial

$90

Buy

171.00%

Upside

Reiterated

11/05/25

Ultragenyx Pharmaceutical (RARE) Gets a Buy from Truist Financial

Yaron Werber

TD Cowen

$86→$75

Buy

125.84%

Upside

Reiterated

11/05/25

TD Cowen Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Laura Chico

Wedbush

$35

Hold

5.39%

Upside

Reiterated

11/05/25

Maxwell Skor

Morgan Stanley

$55

Buy

65.61%

Upside

Reiterated

11/05/25

Ultragenyx Pharmaceutical Positioned for Success with Strategic Financing and Promising Setrusumab Trials

Sami Corwin

William Blair

Buy

―

Reiterated

11/05/25

Positive Outlook for Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Financial Strength and Product Growth

Tazeen Ahmad

Bank of America Securities

$74→$72

Buy

116.80%

Upside

Reiterated

11/05/25

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Bank of America Securities

Luca Issi

RBC Capital

$77→$72

Buy

116.80%

Upside

Reiterated

11/05/25

RBC Capital Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Ram Selvaraju

H.C. Wainwright

$80

Buy

140.89%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Exelixis (NASDAQ: EXEL)

Joseph Schwartz

Leerink Partners

Buy

―

Reiterated

09/08/25

Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ultragenyx Pharmaceutical

1 Month

xxx

Success Rate

14/21 ratings generated profit

Average Return

+5.03%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.03% per trade.

3 Months

xxx

Success Rate

13/21 ratings generated profit

Average Return

+2.02%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +2.02% per trade.

1 Year

Joon LeeTruist Financial

Success Rate

10/21 ratings generated profit

Average Return

+6.39%

reiterated a buy rating last month

Copying Joon Lee's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +6.39% per trade.

2 Years

xxx

Success Rate

12/30 ratings generated profit

Average Return

+10.51%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of +10.51% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RARE Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RARE has received 18 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. RARE average Analyst price target in the past 3 months is 76.31.

Each month's total comprises the sum of three months' worth of ratings.

RARE Financial Forecast

RARE Earnings Forecast

Next quarter’s earnings estimate for RARE is -$1.17 with a range of -$1.87 to -$0.62. The previous quarter’s EPS was -$1.81. RARE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.

RARE Sales Forecast

Next quarter’s sales forecast for RARE is $189.47M with a range of $179.23M to $197.49M. The previous quarter’s sales results were $159.93M. RARE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.

RARE Stock Forecast FAQ

What is RARE’s average 12-month price target, according to analysts?

Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is 76.31.

What is RARE’s upside potential, based on the analysts’ average price target?

Ultragenyx Pharmaceutical has 129.77% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RARE a Buy, Sell or Hold?

Ultragenyx Pharmaceutical has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.

What is Ultragenyx Pharmaceutical’s price target?

The average price target for Ultragenyx Pharmaceutical is 76.31. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $35.00. The average price target represents 129.77% Increase from the current price of $33.21.

What do analysts say about Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of RARE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

RARE Analyst Ratings

RARE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ultragenyx Pharmaceutical

RARE Analyst Recommendation Trends

RARE Financial Forecast

RARE Earnings Forecast

RARE Sales Forecast

RARE Stock Forecast FAQ

Detailed List of Analyst Forecasts